Skip to main content
SpringerLink
Log in

Long-term denosumab linked with dental, jaw complications

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. ONJ = osteonecrosis of the jaw

  2. FREEDOM = Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months. During the 3-year international randomised, placebo-controlled FREEDOM trial, women with postmenopausal osteoporosis received subcutaneous denosumab injections (60mg every 6 months). Upon completion of this trial, women were eligible to enrol in the FREEDOM Extension trial in which patients received up to 7 additional years of denosumab.

Reference

  • Watts NB, et al. Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab for up to 10 Years. Journal of Clinical Endocrinology and Metabolism : [17 pages], 13 Feb 2019. Available from: URL: http://dx.doi.org/10.1210/jc.2018-01965

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Long-term denosumab linked with dental, jaw complications. Reactions Weekly 1742, 10 (2019). https://doi.org/10.1007/s40278-019-58468-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-58468-8

Search

Navigation